We could not find any results for:
Make sure your spelling is correct or try broadening your search.
PCI Biotech second half 2023 interim results Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim...
PCI Biotech: Invitation to second half interim 2023 results presentation Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half...
PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research...
PCI Biotech: European patent for mRNA delivery with fimaNAc Oslo (Norway), 7 September 2023 – PCI Biotech (OSE: PCIB), a biopharmaceutical company, today announces that the European Patent...
PCI Biotech: Employee share option scheme Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In...
PCI Biotech: Write-down of share capital registered Oslo, Norway, 1 September 2023 – PCI Biotech Holding ASA (OSE: PCIB) Reference is made to the resolution made by the Annual General Meeting...
PCI Biotech first half 2023 interim results Oslo (Norway), 31 August 2023 – PCI Biotech (OSE: PCIB), today announces its interim first half 2023 results. Please find enclosed the report and...
PCI Biotech: Invitation to first half interim 2023 results presentation Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 51 | 51 | 51 | 524 | 51 | DE |
52 | 0 | 0 | 51 | 51 | 51 | 824 | 51 | DE |
156 | 0 | 0 | 51 | 51 | 51 | 5199 | 51 | DE |
260 | 0 | 0 | 51 | 51 | 51 | 3951 | 51 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions